Wearable Cardioverter Defibrillators Market

Executive Summary

Wearable Cardioverter Defibrillators Market was valued at US $5.05 billion in 2021 and is projected to grow at 7.40% CAGR over the forecast period to reach US $7.75 billion by 2027. Wearable Cardioverter Defibrillators Market represented US $0.67 billion opportunity over 2019-2021 and estimated to create US $2.70 billion opportunity in 2027 over 2021.

Wearable Cardioverter Defibrillators from Consainsights analyses the Wearable Cardioverter Defibrillators Market in the Life Sciences industry over the forecast period to 2027.

Wearable Cardioverter Defibrillators research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Wearable Cardioverter Defibrillators segmentation includes Demography, End User and Geography.

Based on the Demography, the Wearable Cardioverter Defibrillators analysis covers Pediatric, Adults, Geriatric.

In Demography segment, Pediatric segment has highest cagr growth of 6.55%.

Based on the End User, the Wearable Cardioverter Defibrillators analysis covers Home, Hospitals and Cardiology Clinics, Others end user.

In End User segment, Home segment has highest cagr growth of 6.55%.

Based on the region, the Wearable Cardioverter Defibrillators analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include LivaNova PLC, Koninklijke Philips N.V., Zoll medical Corporation, Stryker Corporation, Medtronic PLC, Nihon Kohden corporation, Kestra Medical Technologies Inc., Boston Scientific Corporation, Element Science and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Demography

Introduction

In 2021, Pediatric segment has the highest revenue of US $2.17 billion and is expected to grow at CAGR of 6.55% by 2027 Pediatric segment has highest cagr growth of 6.55%.

Pediatric

Pediatric segment was valued at US $1.88 billion in 2019 and is projected to grow at 6.55% CAGR over the forecast period to reach US $3.33 billion by 2027. Pediatric segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.16 billion opportunity in 2027 over 2021.

Adults

Adults segment was valued at US $1.07 billion in 2019 and is projected to grow at 6.55% CAGR over the forecast period to reach US $1.90 billion by 2027. Adults segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.66 billion opportunity in 2027 over 2021.

Geriatric

Geriatric segment was valued at US $1.43 billion in 2019 and is projected to grow at 6.55% CAGR over the forecast period to reach US $2.53 billion by 2027. Geriatric segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.88 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Home segment has the highest revenue of US $2.60 billion and is expected to grow at CAGR of 6.55% by 2027 Home segment has highest cagr growth of 6.55%.

Home

Home segment was valued at US $2.25 billion in 2019 and is projected to grow at 6.55% CAGR over the forecast period to reach US $3.99 billion by 2027. Home segment represented US $0.35 billion opportunity over 2019-2021 and estimated to create US $1.39 billion opportunity in 2027 over 2021.

Hospitals and Cardiology Clinics

Hospitals and Cardiology Clinics segment was valued at US $2.10 billion in 2019 and is projected to grow at 6.55% CAGR over the forecast period to reach US $3.73 billion by 2027. Hospitals and Cardiology Clinics segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.30 billion opportunity in 2027 over 2021.

Others end user

Others end user segment was valued at US $0.02 billion in 2019 and is projected to grow at 6.55% CAGR over the forecast period to reach US $0.03 billion by 2027. Others end user segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.